No other significant differences were observed in other adverse reactions.<h4>Conclusion</h4>RAd-p53 combined with CT/RT/CRT for the treatment of cervical cancer showed significant advantages in efficacy and safety compared to those in the CT/RT/CRT group. The gene discussed is TP53; the disease is cervical cancer.